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Almost 30 years ago, overexpression of HMGA proteins was associated with malignant
phenotype of rat thyroid cells transformed with murine retroviruses. Thereafter, several
studies have analyzed HMGA expression in a wide range of human neoplasias. Here, we
summarize all these results that, in the large majority of the cases, confirm the association
of HMGA overexpression with high malignant phenotype as outlined by chemoresistance,
spreading of metastases, and a global poor survival. Even though HMGA proteins’ over-
expression indicates a poor prognosis in almost all malignancies, their detection may be
particularly useful in determining the prognosis of breast, lung, and colon carcinomas,
suggesting for the treatment a more aggressive therapy. In particular, the expression of
HMGA2 in lung carcinomas is frequently associated with the presence of metastases.
Moreover, recent data revealed that often the cause for the high HMGA proteins levels
detected in human malignancies is a deregulated expression of non-coding RNA. There-
fore, the HMGA proteins represent tumor markers whose detection can be a valid tool for
the diagnosis and prognosis of neoplastic diseases.
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TUMOR MARKERS
In presence of an evident tumor mass in the organism, cancer
cells tend to produce high levels of particular substances collec-
tively named tumor markers. Tumor markers are generally found
in body fluids (including blood serum and urine) and tissues
of several cancer patients and are mainly represented by protein
macromolecules (1). However, the use of such markers in clini-
cal diagnostic shows some critical aspects. Indeed, conditions not
related to the presence of tumor could increase their levels, while
patients affected by cancer could not display an increase of their
tumor markers, due to a specific intrinsic variability. Tumor mark-
ers could be associated with a particular type of cancer or with
multiple cancers, but no marker has been virtually associated with
any specific cancer type so far. Nevertheless, in some instances,
markers are very useful in clinical practice, and currently about
20 markers have been characterized and are used (1), but still for
several kind of cancers, no marker is available.
To correctly make pathological report, the evaluation of tumor
marker needs to be completed with other kind of analysis, like
assessment of bioptic tumoral tissue. Moreover, during the admin-
istration of therapeutic regimen, evaluation of particular tumor
markers could be used to check the patients’ response, while after
treatment, they can be used to monitor recurrence of cancer (1).
However, the aim of current and future studies is the detection of
tumor markers before the treatment is starting, allowing the most
appropriate choice for anti-cancer therapy.
About 30 years ago, the high mobility group A (HMGA) pro-
teins were suggested to represent a powerful tumor marker in
relation to malignancies. Indeed, the analysis of chromatin-related
proteins in rat thyroid cells transformed by acute murine retro-
viruses revealed an abundant expression of these proteins only in
fully transformed thyroid cells able to grow in semisolid media
and to induce formation of tumors in nude mice (2, 3). Con-
versely, these proteins were not expressed at all in uninfected cells
or retrovirally infected ones, that did not show the above men-
tioned growth characteristics, despite having lost their thyroid
differentiation markers (3).
HMGA proteins are encoded by two genes, HMGA1 and
HMGA2, located at chromosome 6p21 and 12q13–15, respectively.
HMGA1 gene generates two proteins, HMGA1a and HMGA1b,
by alternative splicing. The three proteins of the HMGA family
(HMGA1a, HMGA1b, and HMGA2) share an analogous structure
(107, 96, and 108 amino acids, respectively), being well preserved
alongside the evolution (4, 5). They contain three AT-hook basic
domains conferring them the ability to bind the DNA minor
groove at sequences rich of A and T nucleotides, and to assem-
ble transcriptional or enhancer complexes on chromatin (6). An
additional COOH-terminal domain still maintains an unchar-
acterized activity. Specifically, HMGA1a contains additional 11
amino acids between the first two AT-hook domains if compared
with HMGA1b, and both are lacking the COOH-domain that,
conversely, is present in HMGA2 (7). In addition, HMGA1a and
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HMGA1b are different from HMGA2 in at least two amino acidic
stretches of 25 and 12 residues, respectively.
As far as the HMGA expression is concerned, these two genes
are both abundantly expressed in embryonic phases, whereas they
are present at very low levels in adult tissues (8, 9). In particular,
HMGA2 is only, very weakly, expressed in preadipocytic proliferat-
ing cells (10), spermatids, and spermatocytes (11, 12). Conversely,
they have been found abundantly overexpressed in human malig-
nancies that suggested causal role for carcinogenesis and tumor
progression, as pointed out by the generation and characterization
of several experimental models all showing for HMGA a powerful
transforming ability (13–16).
Their crucial role in the diverse phases of development has been
demonstrated by the generation of hmga1 and hmga2 knock-out
(ko) mice (17). In particular, hmga1 ko and heterozygous mice
developed cardiac hypertrophy (18) and type 2 diabetes (19), sug-
gesting a role of this protein in the growth of cardiomyocytic cells
and in the modulation of insulin pathway. Interestingly, heterozy-
gous and null hmga2 mice displayed a reduction of body size of 25
and 60% respectively (“pygmy” phenotype) in comparison with
the wild-type (wt) mice, suggesting the involvement of hmga2 in
the regulation of body size and in the adipocytic differentiation
(8, 10). It is worth to note that the concurrent knocking out of
both hmga1 and hmga2 resulted in a reduction of mouse body
size of about 80%, generating the so-called “superpygmy” pheno-
type (20). The ability of the HMGA proteins to activate the E2F1
transcriptional activity likely accounts for this phenotype (21).
HMGA AND COLON CANCER
The role of HMGA proteins in cancer and, in particular HMGA1,
has been widely evaluated in colorectal carcinomas (22, 23)
(Table 1).
Several studies reported that HMGA1 was abundantly
expressed in colon carcinoma tissue and, conversely, almost unde-
tectable in non-pathological mucosa. Interestingly, the overexpres-
sion of HMGA1 was strongly associated with invasive ability, the
staining being more intense in invasion-positive cases in compar-
ison to invasion-negative ones (22), in advanced stage (T3 and
T4 tumors) and with the presence of distant, but not regional,
metastases. It is worth noting that HMGA1 expression (percent-
age of cells and intensity) increased gradually from pre-malignant
stages of colorectal carcinoma to adenoma (characterized by mild
to severe atypia) up to carcinoma. Conversely, non-neoplastic
polyps did not show HMGA1 overexpression (22, 23). Therefore,
these findings seem to indicate that HMGA1 overexpression is
associated with early transformation, rather than with colon cell
hyperproliferation.
It has been observed that RAS oncogene, activated in a large set
of colorectal carcinomas, plays an important role in the mod-
ulation of HMGA1 expression. In fact, it is able to induce its
expression through the activation of two binding sites respon-
sive to SP1 and AP1 transcription factors (24). In addition, the
5′ region of HMGA1 gene contains also two binding sites for the
β-catenin/TCF-4 complex, whose signal transduction activation
represents a critical step in colorectal carcinogenesis (25).
As far as the role of HMGA2 in colorectal cancer is concerned,
the involvement of this gene is still controversial. Indeed, whereas
Table 1 | Overexpression of HMGA proteins in several human solid
malignancies.
Type of cancer HMGA1 HMGA2
Colon and rectum Abe et al. (22) Helmke et al. (26)
Chiappetta et al. (23) Li et al. (27)
Cleynen et al. (24) Wang et al. (28)
Bush et al. (25)
Breast Chiappetta et al. (33) Wend et al. (35)
Mansueto et al. (34) Jones et al. (36)
Pancreas Piscuoglio et al. (37) Piscuoglio et al. (37)
Hristov et al. (38)
Ovary Masciullo et al. (39) Mahajan et al. (40)
Califano et al. (41)
Hetland et al. (42)
Wu et al. (43)
Lung Zhang et al. (44) Rice et al. (45)
Kettunen et al. (46) Kumar et al. (47)
Zhang et al. (48)
Esophagus Chen et al. (51)
Testis Franco et al. (52) Franco et al. (52)
one study reported that HMGA2 is overexpressed only in 50%
of colon carcinoma tissues in comparison to the average expres-
sion of normal adjacent mucosa (26), another one showed that
HMGA2 expression (evaluated as percentage of stained cells)
progressively increased with the severity of carcinoma grade
(Dukes’ A–D), in any case, it is absent in non-neoplastic and
early adenomas (27). Interestingly, epithelial cells overexpressing
HMGA2 resulted located at the invasive front of tissue undergo-
ing epithelial–mesenchymal transition (EMT), and a particular
association between HMGA2 overexpression, strong β-catenin
staining, and loss of E-cadherin in metastatic lesions was found
(27). Finally, it has been also reported that HMGA2 overexpression
promotes metastasis formation and affects survival of colorectal
cancer patients (28).
Recently, very important advances have been achieved in
the identification of mechanisms underlying the development
of colon carcinomas. These studies elucidate several pathways
involved in the pathogenesis of colonic adenocarcinomas yield-
ing to a subclassification as well as different treatment strategies.
Then, it would be very important to correlate the expression of
the HMGA proteins with genetic lesions, putting the detection of
the HMGA proteins as necessary tool for the appropriate choice
of colon cancer therapy.
HMGA AND BREAST CANCER
Ongoing studies have analyzed HMGA1 expression in breast car-
cinomas by using a tissue microarray (TMA) containing more
than 1000 carcinoma samples, mainly ductal histotype, complete
for the follow-up. HMGA1, not detectable in normal breast tissue,
resulted overexpressed in the vast majority of samples analyzed,
but no particular association was found with clinico-pathological
parameters. Intriguingly, the overexpression of HMGA1 positively
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correlated with Her2/neu expression and progesterone receptor
(PR), while surprisingly, was negatively associated with estrogen
receptor (ER). Therefore, these findings suggested for HMGA1 a
role in the response to hormonal treatment of particular kind
of breast carcinomas. In fact, while it is reported that PR+
breast carcinomas are responsive to hormonal treatment, con-
versely, ER−/PR+ carcinomas tend to appear in premenopausal
and younger patients (29–31) with a worse outcome if com-
pared to younger ER+/PR+ patients (32). Hence, overexpression
of HMGA1 could have a prognostic significance based on the
endocrine context, probably by influencing the hormonal response
and the outcome.
These results confirm previous published data (33) showing
that HMGA1 staining was very intense in 40% of hyperplastic
lesions characterized by cellular atypia and 60% of ductal carci-
nomas, whereas the staining was weak in fibroadenomas and in
hyperplastic lesions without cellular atypia (Table 1). The same
study showed no HMGA1 expression in normal breast tissue
(33). These authors also reported that HMGA1 overexpression
was comparable between ductal carcinomas of different histolog-
ical grade, and was associated with c-erbB2 expression (33). It is
noteworthy that the analysis of lobular carcinomas, even though
performed on a limited number of samples, always showed an
intense HMGA1 staining (33, 34).
Interestingly, in breast carcinoma, HMGA1 takes part in an
important regulatory circuitry involving CBX7 and miR-181b
microRNA (miRNA) (34) (Figure 1A). HMGA1 enhances the
expression of miR-181b, which in turn, represses the translation of
CBX7 mRNA. The transcription of CBX7 is also directly repressed
by HMGA1 itself (34) (Figure 1A).
Interesting results were obtained by analyzing HMGA2 expres-
sion in breast tumors coming from different geographical areas:
14 samples of breast cancers from African-American patients, 31
samples from Caucasian-American patients, and 14 samples from
German patients. A strong nuclear expression of HMGA2 was
observed only in the triple negative breast cancers (TNBC), but not
in triple positive (TPBC) samples and in “normal” breast tissues
adjacent to TNBC samples (35).
HMGA2 has been also detected in phyllodes breast cancers
where it was always overexpressed in border line and malig-
nant neoplasias and rarely in benign cases (36), suggesting its
involvement during benignity to malignancy transition.
HMGA AND PANCREATIC CARCINOMA
Several reports indicated that HMGA1 and HMGA2 are abun-
dantly expressed in pancreas adenocarcinomas, where overex-
pression of HMGA1 correlates with advanced grade and, though
less frequently, in pancreas intraepithelial neoplasias (PanIN) (37)
FIGURE 1 |The network of HMGA regulatory mechanisms in human
carcinomas. (A) In breast carcinoma, HMGA1 is able to simultaneously
repress the expression of CBX7 and induce the expression of miR-181b.
This latter, together with CBX7, takes part to a reciprocal regulation.
(B) HMGA2, overexpressed in lung carcinomas, acts as competing
endogenous RNA for let-7, allowing the activation of the TGF-beta signaling
through the upregulation of TGFBR3. Decreased expression of TTF-1 in
lung carcinomas allows the overexpression of HMGA2 protein directly, by
releasing the transcriptional block on its promoter, and indirectly, by
removing the translational block due to miR-33b. HMGA1 is able to induce
the expression of miR-222, which in turn can target p27kip1 and PPP2R2A,
then activating the AKT signaling. (C)The loss of miR-34b expression in
cancer cells allows the overexpression of HMGA1, which in turn alters the
miR-34b pathway by repressing it and its inducer p53. (D)The presence of
several let-7 binding sites in the 3′ untranslated regions of HMGA1,
HMGA2, and relative pseudogenes (HMGA1P, HMGA2P) alters the
epigenetic modulation of HMGA2 and HMGA1 themselves (respectively),
allowing their overexpression after decoy of let-7 microRNA. Dashed
rectangles/ovals and lines represent decreased expression or loss of
regulatory action, respectively.
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(Table 1). Conversely, HMGA1 and HMGA2 were not expressed
in normal pancreas. Interestingly, HMGA1 and HMGA2 overex-
pression correlates with the loss of differentiation and with the
presence of lymph node metastases, indicating their involvement
in neoplastic transformation and progression (37). The correlation
of HMGA overexpression with the acquisition of a more advanced
cancer grade is also corroborated by the association found with the
poor prognosis of pancreas carcinoma patients, that in general is
very short due to high aggressiveness of this type of cancer (37, 38).
Accordingly, all these observations suggest the crucial role
played by either HMGA1 and HMGA2 during the progression
toward malignancy of pancreatic neoplasias.
HMGA AND OVARIAN CARCINOMA
HMGA1 was not expressed in normal epithelium surface where
adenocarcinomas originated, but it was highly expressed in
invasive ovarian carcinomas, and weakly expressed in ovarian
carcinomas with low invasive potential (39) (Table 1).
HMGA2 was found to be abundantly overexpressed in pap-
illary serous carcinomas (high grade) and carcinosarcoma (40).
Moreover, HMGA2 overexpression correlated with low levels of
let-7, a miRNA able to target and repress HMGA2, and with
p53 (40). A strong association has been found also with body
mass index (BMI) and a combined analysis of these two variables
is able to predict the shorter disease-free survival (41). Another
study showed that HMGA2 expression did not correlate with the
response to chemotherapy and survival, while it was correlated
with the expression of several proteins both positively and nega-
tively. Among those with positive correlation, there are Nestin, a
cancer stem cell marker, and the gap junction member claudin-7.
The negative correlation was found with the mRNA correspond-
ing to the E-cadherin repressor SIP1 (42). The role of HMGA2 in
the induction and progression of ovarian cancer has been conclu-
sively demonstrated by a study where HMGA2 was reported to be
able to increase proliferation, migration, and metastatic properties
of ovarian cancer cells (43).
HMGA AND LUNG CANCER
HMGA1 and HMGA2 proteins were overexpressed in non-small
cell lung carcinomas (NSCLC), in both squamous and adenocar-
cinoma histotypes, in comparison with normal lung and benign
tissues (44–46) (Table 1). HMGA2 intense nuclear expression was
strongly associated with metastases and poor prognosis and, as
assessed by Cox multivariate analysis, HMGA2 represents an inde-
pendent prognostic factor (45). A more recent study confirmed
that HMGA2 is highly expressed in metastatic lung adenocarci-
noma, where it contributes to cancer progression and metastasis
by acting as a competing endogenous RNA for let-7 miRNA
family (47). Moreover, the competing action of HMGA2 over-
expression is able to activate the TFG-beta signaling by leading
to the upregulation of the TGF-beta co-receptor Tgfbr3 (47).
Therefore, HMGA2 overexpression would enhance cancer pro-
gression, both as a protein-coding gene and as a non-coding
RNA (47) (Figure 1B). HMGA1 and HMGA2 may have a role
in NSCLC cancer progression also by regulating the expression
of miRNAs. Indeed, it has been reported that at least HMGA1
is able to directly regulate the expression of miR-222 in NSCLC
cells (48). Since it has been demonstrated that miR-222 can target
p27kip1, a critical regulator of cell cycle (49), and the phosphatase
2A subunit B (PPP2R2A), which inhibits Akt phosphorylation
(48), we can assess that HMGA overexpression contributes to
NSCLC progression by dysregulating cell cycle and Akt signaling
(48) (Figure 1B).
An important role in the regulation of HMGA2 expression in
lung carcinomas seems to be played by TTF-1. In fact, lack of
TTF-1 expression is a constant feature of poorly differentiated
lung carcinomas. It has been shown that TTF-1 repressed HMGA2
expression, directly and indirectly, by inducing the expression of
miR-33a, which in turn affects HMGA2 mRNA. As consequent
effect, the loss of TTF-1 triggers the overexpression of HMGA2
(45, 50) (Figure 1B).
It is worth to note that there are no studies reporting HMGA
expression in lung neuroendocrine tumors, or correlating HMGA
expression with the major pathways underlying lung adenocarci-
noma development. Then, we believe that future studies should be
addressed in this direction.
HMGA AND ESOPHAGEAL CARCINOMA
HMGA1 and HMGA2 evaluation in esophageal carcinoma
revealed interesting differences between adenocarcinoma and
squamous histotypes (Table 1). In fact, increasing HMGA1 levels
were observed going from low- to high-grade dysplasia (HGD) and
adenocarcinoma (51). Conversely, HMGA1 mRNA and protein
levels did not show any significant difference between squamous
carcinoma and normal adjacent tissue. Interestingly, studies in
progress in our laboratory reveal high HMGA2 expression in squa-
mous carcinomas histotype and, conversely, its absence in normal
tissue.
HMGA AND TESTICULAR TUMORS
Testicular germ cell tumors (TGCTs) represent an interesting case
where the evaluation of HMGA proteins is very useful to make dif-
ferential diagnosis (Table 1). Indeed, while HMGA1 was expressed
in seminomas and embryonal carcinomas, by contrast, it was not
detected in yolk sac carcinomas and teratomas (52). The same
study reported that HMGA2 was expressed in embryonal and yolk
sac carcinomas, but not in seminomas and teratomas (52).
EPIGENOMIC REGULATION OF HMGA PROTEIN LEVELS
Several recent reports have highlighted the post-transcriptional
repression of HMGA proteins by non-coding RNAs and, in par-
ticular, numerous miRNAs with this activity have been iden-
tified (let-7a, miR-15, miR-16, miR-26a, miR-34b, miR-196a2,
miR-326, miR-432, miR-548c-3p, miR-570, miR-603) (53, 54).
In most human carcinomas analyzed, quite a lot of these miR-
NAs were underexpressed, whereas HMGA proteins were overex-
pressed. In fact, low levels of miR-16 were associated with loss
of differentiation, lymph node metastases, and short overall sur-
vival (Kaplan–Meyer analysis) of colorectal carcinoma patients,
indicating miR-16 as an independent predictive factor of poor
prognosis.
MiR-26 was downregulated in hepatocarcinoma (55) and col-
orectal carcinoma (56), and its loss was significantly linked to the
metastatic phenotype. In addition, miR-26b was drastically down-
regulated in the high aggressive thyroid anaplastic carcinoma,
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whereas its levels did not change in the papillary and follicu-
lar histotypes, less aggressive thyroid carcinoma entities (57). A
strong decrease of let-7 expression levels has been associated with
an aberrant overexpression of HMGA1 and HMGA2 in several
human highly malignant carcinomas (58, 59).
MicroRNAs of the miR-34b family have been found regularly
underexpressed in human carcinomas and the attempt to restore
their physiological levels in cancer cells currently would represent
an innovative and fascinating cancer therapy (60). Intriguingly,
miR-34 and HMGA1 generate an intricate regulatory loop since
HMGA1 is able to negatively regulate the expression of miR-34
(Puca, unpublished observations) and p53 (61), being the latter
able to induce the expression of miR-34. In this process, HMGA1
has a central role since, upon its overexpression, alters miR-34
pathway by acting directly and indirectly on it, through the repres-
sion of p53 (Figure 1C). Because of its involvement in determining
the symmetric or asymmetric cell division, this pathway would
play a critical role in the determination of cancer stem cell fate (61).
To render even more complicated the epigenetic regulation of
HMGA, very recently, a role played by HMGA1 pseudogenes was
proposed. Pseudogenes represent ancestral relatives of genes that
are not any more functional, having lost the possibility to codify for
proteins (62). Recently, two HMGA1 pseudogenes have been iso-
lated (HMGA1P6 and HMGA1P7) that act by binding to miRNAs
targeting HMGA1, then entrapping them, and allow the expres-
sion of functional HMGA1 gene (63). Hence, their overexpression
correlates with high HMGA1 levels and malignancy grade in thy-
roid anaplastic, ovarian, and larynx carcinomas (63). Intriguingly,
in the 3′-UTR of HMGA1, HMGA1P6, and HMGA1P7, poten-
tial binding sites for miRNAs targeting HMGA2 are also located
(Figure 1D). Moreover, it is worthy to note that the 3′-UTR of
HMGA2 carries as many as seven let-7 binding sites, then taking
also part in the modulation of HMGA1 expression levels (47).
Therefore, based on these findings, it becomes clear that not only
pseudogenes, but also HMGA1 and HMGA2 themselves play a
synergistical role in the control of their own expression through
the miRNA decoy mechanism, leading to the establishment of
extremely malignant phenotype.
Finally, the long non-coding (lnc) RNA RPSAP52 able to reg-
ulate the expression of HMGA2 has been recently identified. It
has been found highly overexpressed in pituitary adenomas, where
HMGA2 overexpression plays a central role in the tumorigenesis of
pituitary gland, and in anaplastic thyroid carcinomas that express
very high HMGA2 levels (D’Angelo, unpublished observations).
CONCLUSION AND PERSPECTIVES
The whole collection of published papers dealing with the expres-
sion of HMGA proteins in human malignancies clearly supports
the link between HMGA overexpression and the highly malig-
nant phenotype resulting in poor prognosis of the cancer patients.
The ability to induce EMT, a crucial step during the acquisi-
tion of highly aggressive phenotype, and the ability to confer
resistance to antineoplastic drugs likely account for the associa-
tion of HMGA overexpression with cancer progression. Equally
important appears the ability of HMGA1 to allow CSC to sym-
metrically divide, sustaining their stemness-like phenotype (61).
In this respect, the evaluation of HMGA protein expression might
represent a useful tool for the prediction of prognosis and drug
response. Moreover, the recent finding that the antineoplastic drug
trabectedin exerts its cytotoxic effects on carcinoma cells impair-
ing the function of HMGA proteins (64) may suggest trabectedin
treatment in patients overexpressing HMGA. In addition, fur-
ther evaluation of miRNAs, lnc RNAs, and pseudogenes regulating
HMGA proteins, could reinforce the importance of HMGA1 and
HMGA2 as tumor markers. Currently, a stimulating challenge in
diagnostic research would be the possibility to identify very lit-
tle amounts of HMGA proteins directly in the blood specimens,
either to make an early diagnosis or monitor the efficacy of can-
cer therapy. The optimization of nanotechnology-based devices is
currently in progress and will allow the detection with high speci-
ficity and sensitivity of HMGA1 protein directly in the blood of
CRC patients.
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